PMID- 15925538
OWN - NLM
STAT- MEDLINE
DCOM- 20051103
LR  - 20151119
IS  - 1368-8375 (Print)
IS  - 1368-8375 (Linking)
VI  - 41
IP  - 6
DP  - 2005 Jul
TI  - Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous 
      cell carcinoma.
PG  - 568-79
AB  - Matrix metalloproteinases (MMPs) are proteolytic enzymes that are capable of 
      degrading different substrates within the extracellular matrix, and which are 
      believed to be crucial for tumor invasion and metastasis. Tissue inhibitors of 
      MMPs (TIMPs) can inhibit the action of MMPs but also can show a paradoxical poor 
      prognostic effect. In order to evaluate the prognostic significance of TIMPs, we 
      studied the expression of TIMP-1 and -2 in series of 68 oral squamous cell 
      carcinomas (OSCC) by immunohistochemistry. Expression of TIMP-1 was detected in 
      45 cases (66.2%). In all of these TIMP-1 was expressed in tumoral tissue, and in 
      19 of them also in the surrounding stroma. In cancer tissue, TIMP-1 was observed 
      in three patterns: homogeneous, central and irregular. Immunoreactivity for 
      TIMP-2 was detected in 38 cases (56%) in tumoral tissue and 9 (13.2%) in the 
      stroma. The expression pattern of TIMP-2 was the same three as TIMP-1 and one 
      more: invasive front of tumoral nests. TIMP-1 expression was not correlated with 
      clinical or pathological parameters. However, TIMP-2 was significantly correlated 
      with T stage (p=0.03), TNM stage (p=0.01), local recurrence (p=0.04), and poor 
      survival (p=0.03, odds ratio=2.75). TIMP-1 and TIMP-2 were significantly 
      correlated with cyclin D1 (p=0.04; p=0.015, respectively) and p53 expressions 
      (p=0.02; p=0.04, respectively). Finally, TIMP-1 but no TIMP-2 was associated with 
      the nuclear antigen Ki-67 (p=0.001). These results suggest that TIMP-1 and -2 are 
      expressed in tumoral and stromal tissue in OSCC. TIMP-2 is related to advanced 
      disease, recurrence and poor prognosis.
FAU - de Vicente, Juan Carlos
AU  - de Vicente JC
AD  - Department of Oral and Maxillofacial Surgery, Escuela de Estomalogia, University 
      Hospital of Oviedo, c/Catedratico Jose Serrano, s/n 33006, Oviedo, Spain. 
      jvicente@correo.uniovi.es
FAU - Fresno, Manuel Florentino
AU  - Fresno MF
FAU - Villalain, Lucas
AU  - Villalain L
FAU - Vega, Jose Antonio
AU  - Vega JA
FAU - Lopez Arranz, Juan Sebastian
AU  - Lopez Arranz JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Cyclin D1/metabolism
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Ki-67 Antigen/metabolism
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/*metabolism/pathology
MH  - Neoplasm Proteins/metabolism
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Tissue Inhibitor of Metalloproteinase-1/*metabolism
MH  - Tissue Inhibitor of Metalloproteinase-2/*metabolism
MH  - Tumor Suppressor Protein p53/metabolism
EDAT- 2005/06/01 09:00
MHDA- 2005/11/04 09:00
CRDT- 2005/06/01 09:00
PHST- 2004/12/16 00:00 [received]
PHST- 2004/12/22 00:00 [accepted]
PHST- 2005/06/01 09:00 [pubmed]
PHST- 2005/11/04 09:00 [medline]
PHST- 2005/06/01 09:00 [entrez]
AID - S1368-8375(05)00026-6 [pii]
AID - 10.1016/j.oraloncology.2004.12.008 [doi]
PST - ppublish
SO  - Oral Oncol. 2005 Jul;41(6):568-79. doi: 10.1016/j.oraloncology.2004.12.008.